Test Volume Drives up Neogenomics' Q1 Revenues 73 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Neogenomics today reported a 73 percent uptick in first-quarter revenues year over year as the number of tests performed increased 75 percent.

Revenues for the three months ended March 31 totaled $15.2 million, up from $8.8 million a year ago. The number of tests performed during the quarter increased to 26,932 from 15,396 a year ago.

A net loss of $893,000, or $.02 per share, a year ago was turned into a profit of $603,000, or $.01 per share, in Q1 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.